{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "OBD.L",
  "generated_at": "2026-01-12T05:21:32.879183Z",
  "top_card": {
    "ticker": "OBD.L",
    "company_name": "Oxford BioDynamics Plc",
    "sector": "Healthcare",
    "market_cap_gbp": 10426913,
    "days_active": 38,
    "apex_score_100": 40,
    "confidence_score_100": 50,
    "ai_final_score_25": 10,
    "ai_strength": "MODERATE",
    "timing_regime": "TOO_EARLY",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - TOO_EARLY timing with 40/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Oxford BioDynamics Plc",
      "sector": "Healthcare",
      "industry": "Diagnostics & Research",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 10426913,
      "current_close_price": 0.243
    },
    "basics": {
      "ticker": "OBD.L",
      "current_price": 0.243,
      "ath": 125.0,
      "atl": 0.203,
      "ath_date": "2021-03-23",
      "atl_date": "2025-12-31",
      "week_52_high": 1.3,
      "week_52_low": 0.203,
      "week_52_high_date": "2025-01-10",
      "week_52_low_date": "2025-12-31",
      "drawdown_from_ath_pct": 99.81,
      "data_start": "2020-01-02",
      "data_end": "2026-01-09",
      "total_bars": 1521
    },
    "latest_signal": {
      "date": "2025-12-02",
      "scan_date": "2026-01-09",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 0.254,
      "drawdown_pct": 87.9,
      "ai_score": 8.0,
      "rsi": 41.3,
      "cycle_position": 0.0275,
      "holding_period_days": 38,
      "current_pnl_pct": -4.33,
      "rally_state": "accumulating",
      "distance_from_high_pct": -8.3,
      "Rally_Count": 0,
      "days_since_last_high": 9,
      "last_high_date": "2026-01-02",
      "lock_in_reached": false,
      "lock_in_date": NaN,
      "best_rally_pct": 4.33
    },
    "best_historical_signal": {
      "signal_date": "2022-04-06",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "entry_price": 16.0,
      "peak_price": 52.0,
      "peak_date": "2023-10-03",
      "rally_pct": 225.0,
      "days_to_peak": 545,
      "ai_score": 11.0
    },
    "all_historical_signals": [
      {
        "signal_id": "OBD.L_2022-02-24",
        "signal_date": "2022-02-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 22.5,
        "current_price": 0.243,
        "current_return_pct": -98.92,
        "best_rally_pct": 108.89,
        "best_rally_date": "2023-10-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.48,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 1417,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2022-02-25",
        "signal_date": "2022-02-25",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 22.1,
        "current_price": 0.243,
        "current_return_pct": -98.9,
        "best_rally_pct": 112.67,
        "best_rally_date": "2023-10-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.48,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 1416,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2022-03-02",
        "signal_date": "2022-03-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 22.2,
        "current_price": 0.243,
        "current_return_pct": -98.91,
        "best_rally_pct": 111.71,
        "best_rally_date": "2023-10-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -99.48,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 1411,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2022-04-06",
        "signal_date": "2022-04-06",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 16.0,
        "current_price": 0.243,
        "current_return_pct": -98.48,
        "best_rally_pct": 193.75,
        "best_rally_date": "2023-10-03",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -99.48,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 1376,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-03-14",
        "signal_date": "2024-03-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.34,
        "current_price": 0.243,
        "current_return_pct": -97.4,
        "best_rally_pct": 4.71,
        "best_rally_date": "2024-03-18",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.52,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 668,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-03-15",
        "signal_date": "2024-03-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.48,
        "current_price": 0.243,
        "current_return_pct": -97.44,
        "best_rally_pct": 3.16,
        "best_rally_date": "2024-03-18",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.52,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 667,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-03-18",
        "signal_date": "2024-03-18",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.78,
        "current_price": 0.243,
        "current_return_pct": -97.52,
        "best_rally_pct": -0.82,
        "best_rally_date": "2024-03-20",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 664,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-03-19",
        "signal_date": "2024-03-19",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.44,
        "current_price": 0.243,
        "current_return_pct": -97.43,
        "best_rally_pct": 2.75,
        "best_rally_date": "2024-03-20",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.49,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 663,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-04-03",
        "signal_date": "2024-04-03",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 9.3,
        "current_price": 0.243,
        "current_return_pct": -97.39,
        "best_rally_pct": -0.11,
        "best_rally_date": "2024-04-18",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 648,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 8.88,
        "current_price": 0.243,
        "current_return_pct": -97.26,
        "best_rally_pct": 4.62,
        "best_rally_date": "2024-04-18",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.38,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 647,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-05-09",
        "signal_date": "2024-05-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.8,
        "current_price": 0.243,
        "current_return_pct": -96.88,
        "best_rally_pct": 11.41,
        "best_rally_date": "2024-06-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -97.2,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 612,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-08-30",
        "signal_date": "2024-08-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.04,
        "current_price": 0.243,
        "current_return_pct": -95.98,
        "best_rally_pct": -3.48,
        "best_rally_date": "2024-09-04",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 499,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-02",
        "signal_date": "2024-09-02",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.75,
        "current_price": 0.243,
        "current_return_pct": -95.77,
        "best_rally_pct": 1.39,
        "best_rally_date": "2024-09-04",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -95.83,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 496,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-09",
        "signal_date": "2024-09-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.38,
        "current_price": 0.243,
        "current_return_pct": -95.48,
        "best_rally_pct": -14.68,
        "best_rally_date": "2024-09-13",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 489,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-10",
        "signal_date": "2024-09-10",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 4.3,
        "current_price": 0.243,
        "current_return_pct": -94.35,
        "best_rally_pct": 6.74,
        "best_rally_date": "2024-09-13",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -94.71,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 488,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-11",
        "signal_date": "2024-09-11",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 4.445,
        "current_price": 0.243,
        "current_return_pct": -94.53,
        "best_rally_pct": 3.26,
        "best_rally_date": "2024-09-13",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -94.71,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 487,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-16",
        "signal_date": "2024-09-16",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 3.905,
        "current_price": 0.243,
        "current_return_pct": -93.78,
        "best_rally_pct": -2.94,
        "best_rally_date": "2024-09-19",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 482,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-18",
        "signal_date": "2024-09-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.7,
        "current_price": 0.243,
        "current_return_pct": -93.43,
        "best_rally_pct": 2.43,
        "best_rally_date": "2024-09-19",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -93.59,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 480,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-23",
        "signal_date": "2024-09-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 3.7,
        "current_price": 0.243,
        "current_return_pct": -93.43,
        "best_rally_pct": 2.16,
        "best_rally_date": "2024-10-08",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -93.57,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 475,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-09-26",
        "signal_date": "2024-09-26",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 3.2,
        "current_price": 0.243,
        "current_return_pct": -92.41,
        "best_rally_pct": 18.12,
        "best_rally_date": "2024-10-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -93.57,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 472,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-14",
        "signal_date": "2024-10-14",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.58,
        "current_price": 0.243,
        "current_return_pct": -84.62,
        "best_rally_pct": 39.24,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 454,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-15",
        "signal_date": "2024-10-15",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 1.15,
        "current_price": 0.243,
        "current_return_pct": -78.87,
        "best_rally_pct": 91.3,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 453,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-16",
        "signal_date": "2024-10-16",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.275,
        "current_price": 0.243,
        "current_return_pct": -80.94,
        "best_rally_pct": 72.55,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 452,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-17",
        "signal_date": "2024-10-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.19,
        "current_price": 0.243,
        "current_return_pct": -79.58,
        "best_rally_pct": 84.87,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 451,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-18",
        "signal_date": "2024-10-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.115,
        "current_price": 0.243,
        "current_return_pct": -78.21,
        "best_rally_pct": 97.31,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 450,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-22",
        "signal_date": "2024-10-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.36,
        "current_price": 0.243,
        "current_return_pct": -82.13,
        "best_rally_pct": 61.76,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 446,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-23",
        "signal_date": "2024-10-23",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.2,
        "current_price": 0.243,
        "current_return_pct": -79.75,
        "best_rally_pct": 83.33,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 445,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2024-10-24",
        "signal_date": "2024-10-24",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.29,
        "current_price": 0.243,
        "current_return_pct": -81.16,
        "best_rally_pct": 70.54,
        "best_rally_date": "2024-12-03",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.95,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 444,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-01-15",
        "signal_date": "2025-01-15",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.568,
        "current_price": 0.243,
        "current_return_pct": -57.22,
        "best_rally_pct": 14.61,
        "best_rally_date": "2025-01-17",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -62.67,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 361,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-01-16",
        "signal_date": "2025-01-16",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.63,
        "current_price": 0.243,
        "current_return_pct": -61.43,
        "best_rally_pct": 3.33,
        "best_rally_date": "2025-01-17",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -62.67,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 360,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-01-17",
        "signal_date": "2025-01-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.651,
        "current_price": 0.243,
        "current_return_pct": -62.67,
        "best_rally_pct": -0.15,
        "best_rally_date": "2025-01-20",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 359,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-01-20",
        "signal_date": "2025-01-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.65,
        "current_price": 0.243,
        "current_return_pct": -62.62,
        "best_rally_pct": -0.0,
        "best_rally_date": "2025-01-21",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 356,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-01-22",
        "signal_date": "2025-01-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.243,
        "current_return_pct": -61.12,
        "best_rally_pct": 4.0,
        "best_rally_date": "2025-01-29",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -62.62,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 354,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-01-31",
        "signal_date": "2025-01-31",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.608,
        "current_price": 0.243,
        "current_return_pct": -60.03,
        "best_rally_pct": -1.32,
        "best_rally_date": "2025-02-21",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 345,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-02-04",
        "signal_date": "2025-02-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.5,
        "current_price": 0.243,
        "current_return_pct": -51.4,
        "best_rally_pct": 20.0,
        "best_rally_date": "2025-02-21",
        "rally_state": "accumulating",
        "Rally_Count": 6,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 341,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-02-05",
        "signal_date": "2025-02-05",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.498,
        "current_price": 0.243,
        "current_return_pct": -51.2,
        "best_rally_pct": 20.48,
        "best_rally_date": "2025-02-21",
        "rally_state": "accumulating",
        "Rally_Count": 6,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 340,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-02-12",
        "signal_date": "2025-02-12",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.51,
        "current_price": 0.243,
        "current_return_pct": -52.35,
        "best_rally_pct": 17.65,
        "best_rally_date": "2025-02-21",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 333,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-04-04",
        "signal_date": "2025-04-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.425,
        "current_price": 0.243,
        "current_return_pct": -42.82,
        "best_rally_pct": 41.18,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 282,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-04-07",
        "signal_date": "2025-04-07",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.375,
        "current_price": 0.243,
        "current_return_pct": -35.2,
        "best_rally_pct": 60.0,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 279,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-05-19",
        "signal_date": "2025-05-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.34,
        "current_price": 0.243,
        "current_return_pct": -28.53,
        "best_rally_pct": 76.47,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 237,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-05-20",
        "signal_date": "2025-05-20",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.325,
        "current_price": 0.243,
        "current_return_pct": -25.23,
        "best_rally_pct": 84.62,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 236,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-06-30",
        "signal_date": "2025-06-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.325,
        "current_price": 0.243,
        "current_return_pct": -25.23,
        "best_rally_pct": 84.62,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 195,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-07-01",
        "signal_date": "2025-07-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.3,
        "current_price": 0.243,
        "current_return_pct": -19.0,
        "best_rally_pct": 100.0,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 194,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-07-04",
        "signal_date": "2025-07-04",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.26,
        "current_price": 0.243,
        "current_return_pct": -6.54,
        "best_rally_pct": 130.77,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 191,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-07-07",
        "signal_date": "2025-07-07",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.26,
        "current_price": 0.243,
        "current_return_pct": -6.54,
        "best_rally_pct": 130.77,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 188,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-07-08",
        "signal_date": "2025-07-08",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.255,
        "current_price": 0.243,
        "current_return_pct": -4.71,
        "best_rally_pct": 135.29,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 187,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-07-09",
        "signal_date": "2025-07-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.264,
        "current_price": 0.243,
        "current_return_pct": -7.95,
        "best_rally_pct": 127.27,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 186,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-07-14",
        "signal_date": "2025-07-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.26,
        "current_price": 0.243,
        "current_return_pct": -6.54,
        "best_rally_pct": 130.77,
        "best_rally_date": "2025-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.5,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 181,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-10-22",
        "signal_date": "2025-10-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.305,
        "current_price": 0.243,
        "current_return_pct": -20.33,
        "best_rally_pct": 6.56,
        "best_rally_date": "2025-10-29",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -25.23,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 81,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-11-10",
        "signal_date": "2025-11-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.295,
        "current_price": 0.243,
        "current_return_pct": -17.63,
        "best_rally_pct": 1.69,
        "best_rally_date": "2025-12-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -19.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 62,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-11-11",
        "signal_date": "2025-11-11",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.295,
        "current_price": 0.243,
        "current_return_pct": -17.63,
        "best_rally_pct": 1.69,
        "best_rally_date": "2025-12-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -19.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 61,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-11-12",
        "signal_date": "2025-11-12",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.284,
        "current_price": 0.243,
        "current_return_pct": -14.44,
        "best_rally_pct": 5.63,
        "best_rally_date": "2025-12-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -19.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 60,
        "status": "historical"
      },
      {
        "signal_id": "OBD.L_2025-11-28",
        "signal_date": "2025-11-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.255,
        "current_price": 0.243,
        "current_return_pct": -4.71,
        "best_rally_pct": 17.65,
        "best_rally_date": "2025-12-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -19.0,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 44,
        "status": "active"
      },
      {
        "signal_id": "OBD.L_2025-12-02",
        "signal_date": "2025-12-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.254,
        "current_price": 0.243,
        "current_return_pct": -4.33,
        "best_rally_pct": 4.33,
        "best_rally_date": "2025-12-04",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -8.3,
        "days_since_last_high": 9,
        "lock_in_reached": false,
        "age_days": 40,
        "status": "active"
      }
    ],
    "stats": {
      "total_signals": 54,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 70.34,
      "median_rally_pct": 44.73,
      "best_rally_pct": 225.0,
      "worst_rally_pct": 0.0
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-11 18:23:01 UTC"
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 40/100 indicates moderate opportunity quality",
      "Timing regime: TOO_EARLY",
      "Historical profile: 0 rallies, 4% best run"
    ],
    "main_risk": "Confidence 50/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "OBD.L",
      "latest": [
        {
          "title": "Publication of 2025 Annual Report",
          "announcement_date": "22nd Dec 2025",
          "release_time": "11:00 am",
          "source": "RNS",
          "content": "22 Dec 2025 11:00\nRNS Number : 4871M\nOxford BioDynamics PLC\n22 December 2025\nOxford BioDynamics Plc\n(\n\"\nOBD\n\" or the \"\nCompany\n\" and, together with its subsidiaries, the \"\nGroup\n\"\n)\nPublication of 2025 Annual Report\nOxford, UK - 22 December 2025 -\nOxford BioDynamics Plc (AIM: OBD, the Company),\u00a0a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch\u00ae 3D genomics platform,\nannounces\nthat\nits annual report and accounts for the year ended 30 September 2025 (\"Annual Report\") is available in electronic form\u00a0on its website at\u00a0www.oxfordbiodynamics.com/investors/financial-results. Hard copies of the report (incorporating the Notice of Annual General Meeting) will be posted to shareholders today.\nAs stated in the preliminary results announcement on 16 December 2025, the Company's\u00a0Annual General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 26 January 2026 at 11.00 am.\n-Ends-\nFor further details please contact:\nOxford BioDynamics Plc\nTel: +44 (0)1865 518910\nIain Ross Executive Chairman\nPaul Stockdale, CFO\nShore Capital - Nominated Adviser and Broker\nTel: +44 (0)20 7408 4090\nStephane Auton / Lucy Bowden\nOAK Securities - Joint Broker\nTel: +44 (0)20 3973 3678\nMatthew Clarke / Tim Dainton / Calvin Man\nCamarco - Financial PR\nTel: +44 (0)20\u00a03757 4980\nMarc Cohen / Tilly Butcher / Fergus Young\nOBDFinancial@camarco.co.uk\nNotes to Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently\u00a0OBD\u00a0has two commercially available products: the\nEpiSwitch\u00ae PSE\n(EpiSwitch Prostate Screening test)\u00a0and\nEpiSwitch\u00ae CiRT\n(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.\u00a0CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch\u00ae\u00a0which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.\nOBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.\nThe Group's headquarters and\u00a0UK\u00a0laboratories are in\u00a0Oxford, UK. Its US operations and clinical laboratory are in\u00a0Maryland, USA, along with a reference laboratory in Penang,\u00a0Malaysia.\nOBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website,\nwww.oxfordbiodynamics.com\n, X (@OxBioDynamics) or\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nACSUUORRVKUUUAA"
        },
        {
          "title": "Publication of 2025 Annual Report",
          "announcement_date": "22nd Dec 2025",
          "release_time": "11:00 am",
          "source": "RNS",
          "content": "22 Dec 2025 11:00\nRNS Number : 4871M\nOxford BioDynamics PLC\n22 December 2025\nOxford BioDynamics Plc\n(\n\"\nOBD\n\" or the \"\nCompany\n\" and, together with its subsidiaries, the \"\nGroup\n\"\n)\nPublication of 2025 Annual Report\nOxford, UK - 22 December 2025 -\nOxford BioDynamics Plc (AIM: OBD, the Company),\u00a0a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch\u00ae 3D genomics platform,\nannounces\nthat\nits annual report and accounts for the year ended 30 September 2025 (\"Annual Report\") is available in electronic form\u00a0on its website at\u00a0www.oxfordbiodynamics.com/investors/financial-results. Hard copies of the report (incorporating the Notice of Annual General Meeting) will be posted to shareholders today.\nAs stated in the preliminary results announcement on 16 December 2025, the Company's\u00a0Annual General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 26 January 2026 at 11.00 am.\n-Ends-\nFor further details please contact:\nOxford BioDynamics Plc\nTel: +44 (0)1865 518910\nIain Ross Executive Chairman\nPaul Stockdale, CFO\nShore Capital - Nominated Adviser and Broker\nTel: +44 (0)20 7408 4090\nStephane Auton / Lucy Bowden\nOAK Securities - Joint Broker\nTel: +44 (0)20 3973 3678\nMatthew Clarke / Tim Dainton / Calvin Man\nCamarco - Financial PR\nTel: +44 (0)20\u00a03757 4980\nMarc Cohen / Tilly Butcher / Fergus Young\nOBDFinancial@camarco.co.uk\nNotes to Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently\u00a0OBD\u00a0has two commercially available products: the\nEpiSwitch\u00ae PSE\n(EpiSwitch Prostate Screening test)\u00a0and\nEpiSwitch\u00ae CiRT\n(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.\u00a0CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch\u00ae\u00a0which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.\nOBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.\nThe Group's headquarters and\u00a0UK\u00a0laboratories are in\u00a0Oxford, UK. Its US operations and clinical laboratory are in\u00a0Maryland, USA, along with a reference laboratory in Penang,\u00a0Malaysia.\nOBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website,\nwww.oxfordbiodynamics.com\n, X (@OxBioDynamics) or\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nACSUUORRVKUUUAA"
        },
        {
          "title": "Preliminary Results and Notice of AGM",
          "announcement_date": "28th Feb 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "28 Feb 2025 07:00\nRNS Number : 7974Y\nOxford BioDynamics PLC\n28 February 2025\nOxford Biodynamics Plc\n(\"\nOBD\n\" or the \"\nCompany\n\" and, together with its subsidiaries, the \"\nGroup\n\")\nPreliminary results for the year ended 30 September 2024\nand\nNotice of Annual General Meeting\nOxford, UK - 28 February 2025 -\nOxford BioDynamics Plc (AIM: OBD),\na precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch\u00ae 3D genomics platform\n,\ntoday announces its final results for the year ended 30 September 2024.\nCorporate and operational highlights\n\u00a7\nCPT-PLA Code issued for EpiSwitch PSE Test, allowing reimbursement by US insurers\n\u00a7\nOpening of UK Clinical Laboratory\n\u00a7\nDevelopment of EpiSwitch SCB diagnostic test for canine cancers\n\u00a7\nDevelopment of EpiSwitch NST diagnostic test for colorectal cancer and polyps\nFinancial highlights\n\u00a7\nRevenue of \u00a30.6m (FY23: \u00a30.5m)\n\u00a7\nOther operating income of \u00a30.5m (FY23: \u00a30.8m)\n\u00a7\nOperating loss of \u00a312.9m (FY23: \u00a310.2m)\n\u00a7\nFundraising generating \u00a39.9m (before costs) (April 2024)\n\u00a7\nCash and cash equivalents and fixed-term deposits of \u00a32.8m as at 30 September 2024 (FY23: \u00a35.3m)\nPost-year end highlights\n\u00a7\nFundraising generating \u00a37.35m (before costs) to fund the ongoing business (January 2025)\n\u00a7\nAppointment of Iain Ross as Executive Chairman (January 2025)\n\u00a7\nReal-world data on EpiSwitch CiRT in liver and GI cancers presented at ASCO-GI (January 2025)\n\u00a7\nPeer-reviewed publication of research supporting OBD's EpiSwitch NST for colorectal cancer (February 2025)\n\u00a7\nDistribution agreement with largest private healthcare provider in Romania, Regina Maria (February 2025)\n\u00a7\nVisit to OBD's Oxford HQ by former UK Prime Minister, Rt Hon Rishi Sunak in his role as an Ambassador for Prostate Cancer Research (February 2025)\nIain Ross, Executive Chairman of OBD said:\n\"Notwithstanding the developments and challenges this business has faced over the past year, I believe our world-class clinical tests and pipeline assets remain potentially very valuable. With the support of shareholders our immediate focus is on seeking further meaningful partnerships and collaborations with diagnostic and pharmaceutical companies and increasing direct sales as a route to achieving sustainable commercial success. We are well aware we need to demonstrate clear and rapid progress in order to deliver a substantial increase in shareholder value.\"\nNotice of Annual General Meeting\nThe Company's Annual General Meeting will be held at\u00a03140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 28 March 2025 at 10.00 am.\nThe information included in this announcement is extracted from the Annual Report, which was approved by the Directors on 27 February 2025. Defined terms used in the announcement refer to terms as defined in the Annual Report unless the context requires otherwise. This announcement should be read in conjunction with, and is not a substitute for, the full Annual Report.\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310) (\"UK MAR\"). Upon the publication of this announcement, this inside information (as defined in UK MAR) is now considered to be in the public domain.\n-Ends-\nFor further details please contact:\nOxford BioDynamics Plc\nTel: +44 (0)1865 518910\nIain Ross Executive Chairman\nPaul Stockdale, CFO\nShore Capital - Nominated Adviser and Broker\nTel: +44 (0)20 7408 4090\nAdvisory: Stephane Auton / Lucy Bowden\nBroking: Fiona Conroy\nOAK Securities - Joint Broker\nTel: +44 (0)20 3973 3678\nJerry Keen / Henry Clarke / Damion Carruel\nWG Partners - Joint Broker\nTel: +44 (0)20 3705 9330\nDavid Wilson /\nClaes Sp\u00e5ng /\u00a0Satheesh Nadarajah / Erland Sternby\nCamarco - Financial PR\nTel: +44 (0)20\n3757 4980\nMarc Cohen / Tilly Butcher / Fergus Young\nOBDFinancial@camarco.co.uk\nExecutive Chairman's letter to shareholders\nBackground\nOn 16 December 2024, following an approach from the Oxford BioDynamics Board, I joined the Group, agreeing to do so on the basis that Vulpes Testudo Fund would provide a shareholder loan to the business for up to \u00a31m whilst an immediate emergency fundraising was undertaken. I agreed to lead the fundraising because it was clear to me that this business has some potentially very valuable assets, which provide highly effective and unique solutions to health problems affecting millions of people worldwide, and some first-rate personnel. However, I believe mistakes had been made over the recent past that have contributed to a failure to deliver shareholder value.\nI am pleased to report that in early January 2025 the Company announced it had raised \u00a37.35 million (before expenses) and, following shareholder approval at the General Meeting held on 31 January 2025, I was appointed to the Board as Executive Chairman.\nTo start with, I want to thank our existing shareholders, many of whom, understandably, voiced their frustration and disappointment during the roadshow regarding the Company's progress. Your continued support is appreciated. I also want to warmly welcome the new investors who have joined the register.\nFocus and Realism\nMy remit is to turn this business around, recognising its valuable assets and its potential to become a significant player in the international diagnostics market. The challenge is to bring some\nfocus\nand\nrealism\ninto the way we operate going forward and ensure we avoid the financial position in which the Group found itself at the end of 2024. I don't intend to comment on how this situation arose: a summary of the year ended 30 September 2024 is provided in the financial review which follows.\nIn terms of\nfocus\nand\nrealism\n, one immediate aspect to which I would draw your intention is that, whilst recognising our intellectual property (IP) remains critical and is a bedrock of this business, we have included in the financial statements\nthe impairment of selected patent assets, reflecting the decision to focus short-term resources on the Group's most advanced assets. I want to recognise the scientific excellence within the Company which has provided us with a valuable portfolio of assets, each of which is cutting edge and could result in improving and saving patients' lives. However, I also recognise that, in order to achieve our objectives, we must be financially pragmatic going forward.\nWhere do we go from here?\nAs Executive Chairman, my ultimate objective is to structure and operate the business to optimise shareholder value. In conjunction with the management team, I am undertaking a review of the operational aspects of the business in order to make it more commercially focused and market orientated.\nThere will undoubtedly be some difficult decisions to make and along with a careful review of the current cost base, my goal is to ensure the business is 'fit for purpose' and well-positioned for success. To date there have been aspects of the business where the Group has had to take a \"go it alone\" approach, particularly in the USA, to drive adoption which is laudable, but in my opinion difficult to sustain for a business of our size. I recognise that whilst many good things have been achieved, the Group's commercial goals in terms of test sales have proven unrealistic and not been delivered.\nPartnership & Collaboration\nGoing forward, the company intends to focus more on establishing partnerships and collaborations, across all geographies, as a way of securing commercial and financial success. As necessary, we are prepared to sacrifice upfront value, enter early partnerships and thereby increase the probability of success by working with third parties to accelerate the commercialisation of our assets. If we need to out-license a key asset or enter into an early-stage collaboration to share costs and fund this business, we will do, as we work towards our mission of creating and enhancing sustainable shareholder value. I am acutely aware of the risk and rewards associated with entering into partnerships, but I am also fully aware that our shareholders are looking for a return on their investment and to date, this has been sadly lacking.\nAt the time of writing, we are not ruling out anything and by way of example we are carefully weighing up the pros and cons of the competitive environment in which we operate, the current commercialisation strategy, and the urgent need for third-party validation. I recognise that OBD's 3D genomics KnowledgeBase and the contacts established with pharma and biotech partners over the years since the Company's inception offer significant potential value, but we need to accelerate the exploitation of this to our advantage.\nTo be clear, we are not starting with an empty page as there have been, and are, many good leads and ongoing third-party discussions. However, I intend to instil focus and a sense of urgency into the business to bring these opportunities to fruition. Whilst generating increasing revenue is an absolute priority, we will also seek to raise the external profile and awareness of Oxford BioDynamics and its assets amongst all facets of society including the scientific, academic, governmental and industrial communities and, where applicable, the general public.\nIn the last month we have seen the\nresults of a multi-institutional clinical study published in the peer reviewed journal 'Cancers' confirming the efficacy of\nOBD's EpiSwitch\u00ae\nblood-based No-Stool Test (NST)\nfor accurate detection of early-stage colorectal cancer and pre-cancerous polyps; the announcement of a commercial partnership with Regina Maria, Romania's largest private healthcare provider, serving 5 million patients and a highly publicised visit by Prostate Cancer Research's new ambassador the Right Honourable Rishi Sunak MP to our facilities in Oxford.\nBoard Evolution & Independence\nThere is little doubt that the last twelve months has been very challenging for the OBD Board and Management as well as the Group as a whole and as we move forward, we need to recognise the efforts of those concerned. The Board, chaired by Matthew Wakefield, has, for the last four years, been unstinting in its efforts to support Management and raise funding for the business.\nMatthew, in particular, has dedicated himself to steering the Company through some turbulent times in the recent past, but he has indicated, having recruited me and played his part in the recent successful fundraising, that now is the right time for him to step down from the Board prior to the forthcoming AGM at which the directors will be re-elected. I want to thank Matthew personally and on behalf of the Company for all his efforts, for recruiting me and for agreeing to assist me with the ongoing transition.\nAs I said on the fundraising roadshow - as Executive Chairman I want provide shareholders with optionality going forward such that they can decide either to continue to build and invest in the business or exit it for its true value in due course. The reality is that Oxford BioDynamics is a small player, albeit with a big ambition, but it has yet to prove its worth. I look forward to working with the Board, the management team, the staff and all stakeholders to\nr\nealise true market value for the Company.\nIain G Ross\nExecutive Chairman\nOxford BioDynamics Plc\n27 February 2025\nFinancial review\nThe Group's performance in the year ended 30 September 2024 and its position at that date reflected slower growth in revenues than expected following the launch of the EpiSwitch PSE test in September 2023 and increased fixed costs as a result of the Group's investment in staff and marketing to support its test products. This investment did not generate sufficiently rapid growth in sales to reassure the market and ultimately the Company's revenues from sales of its tests, whilst increased compared to the prior year, were too low to prevent the urgent need for the recent highly dilutive fundraising. The Group's loss before tax for the year ended 30 September 2024 was \u00a311,956,000 (2023: \u00a311,411,000).\nEpiSwitch PSE\nThe Group's EpiSwitch PSE test was launched shortly before the start of the year ended 30 September 2024. During the year more than 700 tests were ordered by c.400 organisations worldwide. Post-year end orders have continued to increase, with over 500 tests sold in the four-month period to the end of January 2025.\nThe test is performed in OBD's CLIA\n\u2020\n- and ISO-accredited clinical laboratories in the US and UK respectively.\nFollowing the launch of the test, the Group invested in targeted online marketing which, alongside a small sales team, would support PSE. From August 2024, this team was supported by the internal transfer of a number of sales managers who had previously been concentrating on growing sales of EpiSwitch CiRT. The level of spend on online advertising for PSE was significantly reduced shortly after the year end and the Group is continuing to monitor the impact of this reduction on sales of the test, particularly to new clinics or doctors.\nEpiSwitch PSE benefits from:\n\u00b7\na unique CPT-PLA\n\u2021\ncode (0433U), enabling reimbursement by US insurers. Reimbursement for the test is regularly received from a growing number of US insurers including Medicare, Humana, United Healthcare and Aetna.\n\u00b7\ndistribution agreements with Goodbody Clinic in the UK, KZT in Turkey and Regina Maria in Romania\n\u00b7\ndirect agreements with organisations and concierge clinics that pay for the test on a 'cash pay' basis, such as The London Clinic in the UK and Doctors Studio in the US\n\u00b7\nendorsement from key opinion leaders such as Garret Pohlman, MD. Dr Pohlman has used over 175 PSE tests to date, sharing real world evidence of how he has used the test in his Nebraska clinic in early January 2025. Dr Pohlman estimates that since adopting the test he has been able to reduce the number of biopsies performed in his clinic by 50% and streamlined his clinical practices\nSufficiently rapid, significant growth in the number of PSE orders is most likely to arise from agreements that can generate large volumes without investment by the Group in, for example, large sales teams. To this end, the Group is focusing on seeking both agreements with large customers (such as UK insurers) and distribution partners for the test. The company has reached a commercial agreement with Regina Maria Private Health Network in January 2025, Romania's largest private healthcare provider, serving 5 million patients, to provide access to both EpiSwitch PSE and EpiSwitch CiRT tests.\nThe potential for PSE to be used as part of a screening programme for prostate cancer was highlighted in a recent Prostate Cancer Research (PCR) report. Analysis by PCR and Deloitte in the report suggested that a population-wide screening programme utilising a test such as PSE alongside PSA and before MRI and biopsy would deliver net benefits (to individuals, the health and care sector and society as a whole).\nEpiSwitch CiRT\nEpiSwitch CiRT accurately identifies patients who will respond to immune checkpoint inhibitor (ICI) therapy with a binary result (responder vs. non-responder), supporting oncologists in first-line treatment planning and making more informed treatment decisions when no benefit or disease progression is observed, or adverse events occur. The test can also identify as candidates for ICI therapy patients for whom other options have been exhausted or who other less accurate tests suggest will not respond to treatment with an ICI.\nCiRT was launched in February 2022, with initial orders coming from early adopter oncologists. The Group initially focused on growing sales through 'peer-to-peer' marketing, facilitated by a team of salespeople. This approach had limited success relative to the costs incurred, but did generate initial evidence of the use and utility of the test. During the year, following the appointment of Dr Ryan Mathis to lead the CiRT vertical, the Group adapted its approach for growing CiRT in two main ways:\n\u00b7\nInclusion in US physicians' guidelines (such as those of the National Comprehensive Cancer Network (NCCN)), which will be key to generating wider uptake of the test. To support an application for CiRT's inclusion in the NCCN Guidelines, the Group initiated the PROWES Registry Study, a prospective observational study involving up to 2,500 patients at up to 12 sites across the US. The Group is able to claim reimbursement for tests processed for patients enrolled into the study as normal under the test's unique CPT-PLA\n\u2021\ncode but also incurs additional per-patient and per-site costs in the administration of the study.\n\u00b7\nWith the majority of CiRT orders now coming from sites participating in PROWES, the Group was able to reallocate several members of the CiRT sales team to work on PSE, from September 2024.\nThe Group is currently developing an early application for guideline inclusion and in this context was pleased to note the presentation of real-world evidence of the clinical utility of CiRT in a cohort of patients with liver (hepatocellular) and gastrointestinal (GI) cancers by Georgetown University Medical Center at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) in January 2025.\nThere were over 670 CiRT orders in the year ended 30 September 2024. This represented a 30% increase on the prior year. However, as noted above, most volume currently comes from sites onboarded to the PROWES study.\nCiRT tests are currently processed in the CLIA-accredited facilities of the Group's partner laboratory, Next Molecular Analytics, and in the Group's UK clinical laboratory.\nFinancial performance\nTogether, sales of the Group's clinical tests generated revenues of \u00a30.4m (2023: \u00a30.2m). Revenue from tests reimbursed by US insurers has effectively been recognised only on final receipt, which delays revenue recognition relative to test performance and cost of sales. Total revenues in the period were \u00a30.6m (2023: \u00a30.5m).\nOther operating income was \u00a30.5m (2023: \u00a30.8m), arising from the Group's two Partnership for Advancing Cancer Therapies (PACT) Awards and its participation in the EU-funded HIPPOCRATES consortium (psoriasis and psoriatic arthritis).\nOverall, the Group's cost base was increased, reflecting additional marketing spend to support PSE and increased headcount, typically in higher cost US-based roles. Higher base salaries were offset by not paying bonuses in respect of the year, such that total staff costs were 1.7% higher than the prior year at \u00a35.5m (2023: \u00a35.4m) even though headcount increased by 13%. Post year-end, the Group reduced headcount in the US and UK as part of its cost-saving activities.\nHigher depreciation and amortisation (\u00a31.5m, 2023: \u00a31.4m) was driven primarily by the full-year impact of the Group's US clinical laboratory (the UK clinical lab commissioned during the period is in the Group's existing UK office and lab building). Non-cash share option charges were increased at \u00a30.5m (2023: \u00a30.3m), mainly as a result of a significant option award to the former Chief Executive Officer during the period. There was a modest increase in the amount spent on lab consumables in internal R&D (\u00a30.8m, 2023: \u00a30.75m).\nAs noted in the Executive Chairman's message and described in more detail in Note 2 to the financial statements, an impairment charge of \u00a30.9m has been recognised in respect of certain families of patents that were previously capitalised. The write-down reflects the limited resources available for the near-term commercialisation of the patents concerned, although to date no decisions have been taken to abandon any of them. The position will be reviewed at subsequent reporting dates.\nThe significant fair value gain on financial liabilities of \u00a31.4m (2023: fair value loss of \u00a31.2m) arises on the estimation of the fair value of the warrants issued by the Company in 2021 and is driven mainly by the reduction in the share price over the year.\nFinance income (unchanged at \u00a30.1m, 2023: \u00a30.1m) reflected higher receipts from bank deposits costs, offset by lower foreign exchange gains. Finance costs were increased at \u00a30.5m (2023: \u00a30.2m), driven mainly by foreign exchange losses.\nCash\nCash and term deposits at 30 September 2024 were \u00a32.8m (30 September 2023: \u00a35.3m), broadly reflecting \u00a39.1m in net receipts from the equity fundraising in April 2024, the Group's operating cash outflow for the year of \u00a310.6m (2023: \u00a39.1m), net tax receipts of \u00a30.4m (2023: \u00a30.8m), capital expenditure of \u00a30.6m (2023: \u00a30.7m) and lease payments of \u00a30.8m (2023: \u00a30.9m).\nCapital expenditure during the period mainly comprised spend on patents to support and expand the Company's intellectual property portfolio as well as development costs for the Group's clinical order management system. Property plant and equipment additions were limited, with some spend on lab equipment in the Group's CLIA-accredited lab in Frederick, MD, as well as purchases of office equipment for new starters.\nFollowing the year end the Group benefited from an interest-free, unsecured, subordinated loan facility of up to \u00a31m, from Vulpes Testudo Fund (which is controlled by Non-Executive Director Stephen Diggle and which, together with the Vulpes Life Sciences Fund is a significant shareholder in the Company). This facility was critical in permitting the Company to complete the recent equity fundraising referred to in the Executive Chairman's letter. As permitted by the terms of the loan, it was subsequently settled through the issuing of new ordinary shares to Vulpes Testudo Fund as part of the fundraising.\nThe Group enters the remainder of 2025 with replenished but limited cash resources. The Directors have concluded, as was the case at the previous year end, that material uncertainties exist which may cast significant doubt on the Group and Company's ability to continue as a going concern. Stakeholders' attention is drawn to the more detailed commentary on the Directors' assessment of the reasonableness of continuing to adopt the going concern assumption in the preparation of the accounts in Note 2.\nPaul Stockdale\nChief Financial Officer\nOxford BioDynamics Plc\n27 February 2025\n\u2020\u00a0CAP-CLIA regulated laboratories are accredited by the College of American Pathologists as being compliant with the Clinical Laboratory Improvement Amendments, 1988 (42 CFR, Part 493).\n\u2021\u00a0A Current Procedural Terminology - Proprietary Laboratory Analysis (CPT-PLA) code is used in the US to report medical and diagnostic services to entities such as health care professionals and payors.\nCONSOLIDATED INCOME STATEMENT\nYEAR ENDED 30 SEPTEMBER 2024\n2024\n2023\n\u00a3000\n\u00a3000\nContinuing operations\nNote\nRevenue\n3\n636\n510\nCost of sales\n(347)\n(244)\nGross profit\n289\n266\nAdmin expenses comprising\n:\nResearch & development costs (excluding staff costs)\n(809)\n(758)\nStaff costs\n(5,495)\n(5,403)\nGeneral & other admin costs\n(4,479)\n(3,411)\nShare option charges\n(514)\n(332)\nDepreciation and amortisation\n(1,466)\n(1,357)\nImpairment loss on intangible assets\n(896)\n-\nTotal admin expenses\n(13,659)\n(11,261)\nOther operating income\n4\n476\n827\nOperating loss\n(12,894)\n(10,168)\nFair value gain / (loss) on financial liabilities designated as FVTPL\n12\n1,349\n(1,246)\nGain reclassified to profit or loss on disposal of foreign operation\n-\n113\nFinance income\n112\n103\nFinance costs\n(523)\n(213)\nLoss before tax\n(11,956)\n(11,411)\nIncome tax\n389\n585\nLoss for the year from continuing operations\n6\n(11,567)\n(10,826)\nLoss attributable to:\nOwners of the Company\n(11,567)\n(10,826)\nNon-controlling interest\n-\n-\n(11,567)\n(10,826)\nEarnings / (loss) per share\nFrom continuing operations\nBasic and diluted (pence per share)\n7\n(4.5)\n(7.3)\nCONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME\nYEAR ENDED 30 SEPTEMBER 2024\n2024\n2023\n\u00a3000\n\u00a3000\nNote\nLoss for the year\n6\n(11,567)\n(10,826)\nExchange differences on translation of foreign operations that may be reclassified to the income statement\n255\n(182)\nTotal comprehensive income for the year\n(11,312)\n(11,008)\nTotal comprehensive income attributable to:\nOwners of the Company\n(11,312)\n(11,008)\nNon-controlling interest\n-\n-\n(11,312)\n(11,008)\nCONSOLIDATED STATEMENT OF FINANCIAL POSITION\nAS AT 30 SEPTEMBER 2024\n2024\n2023*\n\u00a3000\n\u00a3000\nAssets\nNote\nNon-current assets\nIntangible assets\n8\n1,351\n1,913\nProperty, plant and equipment\n9\n1,762\n2,238\nRight-of-use assets\n10\n3,949\n4,759\nDeferred tax asset\n-\n50\nTotal non-current assets\n7,062\n8,960\nCurrent assets\nInventories\n321\n274\nTrade and other receivables\n1,385\n957\nCurrent tax receivables\n513\n686\nFixed-term deposits\n1,000\n-\nCash and cash equivalents\n1,827\n5,250\nTotal current assets\n5,046\n7,167\nTotal assets\n12,108\n16,127\nEquity and liabilities\nCapital and reserves\nShare capital\n11\n3,119\n2,023\nShare premium\n40,149\n32,144\nTranslation reserves\n192\n(63)\nShare option reserve\n3,017\n2,776\nRetained earnings\n(42,119)\n(30,825)\nTotal equity\n4,358\n6,055\nCurrent liabilities\nTrade and other payables\n1,506\n1,707\nWarrant liability\n11\n1,360\nLease liabilities\n1,046\n818\nCurrent tax liabilities\n-\n116\nTotal current liabilities\n2,563\n4,001\nNon-current liabilities\nLease liabilities\n4,694\n5,621\nProvisions\n486\n440\nDeferred tax\n7\n10\nTotal non-current liabilities\n5,187\n6,071\nTotal liabilities\n7,750\n10,072\nTotal equity and liabilities\n12,108\n16,127\n*See Note 2 for details of change in presentation of comparative information\nCONSOLIDATED STATEMENT OF CHANGES IN EQUITY\nYear ended 30 September 2024\nShare\ncapital\nShare premium\nTransla-\ntion\nreserve\nShare\noption\nreserve\nRetained\nearnings\nAttribu-\ntable to\nshare-\nholders\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\nAt 1 October 2023\n2.023\n32.144\n(63)\n2,776\n(30,825)\n6,055\nLoss for the year\n-\n-\n-\n-\n(11,567)\n(11,567)\nOther comprehensive income for the period\n-\n-\n255\n-\n-\n255\nTotal comprehensive income for the period\n-\n-\n255\n-\n(11,567)\n(11,312)\nSubscription for new shares\n1,096\n8,764\n-\n-\n-\n9,860\nTransaction costs for new shares\n-\n(759)\n-\n-\n-\n(759)\nShare option credit\n-\n-\n-\n514\n-\n514\nLapse of vested share options\n-\n-\n-\n(273)\n273\n-\nAt 30 September 2024\n3,119\n40,149\n192\n3,017\n(42,119)\n4,358\nYear ended 30 September 2023\nShare\ncapital\nShare premium\nTransla-\ntion\nreserve\nShare\noption\nreserve\nRetained\nearnings\nAttribu-\ntable to\nshare-\nholders\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\nAt 1 October 2022\n1,004\n19,020\n119\n3,154\n(20,709)\n2,588\nLoss for the year\n-\n-\n-\n-\n(10,826)\n(10,826)\nOther comprehensive income for the period\n-\n-\n(182)\n-\n-\n(182)\nTotal comprehensive income for the period\n-\n-\n(182)\n-\n(10,826)\n(11,008)\nSubscription for new shares\n1,019\n14,368\n-\n-\n-\n15,387\nIssue of warrants to subscribe for new shares\n-\n-\n-\n-\n-\n-\nTransaction costs for new shares\n-\n(1,244)\n-\n-\n-\n(1,244)\nShare option credit\n-\n-\n-\n332\n-\n332\nLapse of vested share options\n-\n-\n-\n(710)\n710\n-\nAt 30 September 2023\n2,023\n32,144\n(63)\n2,776\n(30,825)\n6,055\nCONSOLIDATED STATEMENT OF CASH FLOWSYEAR ENDED 30 SEPTEMBER 2024\n2024\n2023\n\u00a3000\n\u00a3000\nNote\nLoss before tax for the financial year\n6\n(11,956)\n(11,411)\nAdjustments to reconcile loss for the year to net operating cash flows:\nNet interest\n113\n141\nLoss on disposal of property, plant and equipment\n-\n4\nDepreciation of property, plant and equipment\n9\n550\n548\nDepreciation of right-of-use assets\n10\n745\n663\nAmortisation of intangible assets\n8\n171\n146\nImpairment loss on intangible fixed assets\n896\n-\nNet foreign exchange movements\n293\n(122)\nMovement in provisions\n46\n16\nShare based payments charge\n514\n332\nFair value loss / (gain) on financial liabilities\n(1,349)\n1,246\nWorking capital adjustments:\nIncrease in trade and other receivables\n(427)\n(448)\n(Increase) / decrease in inventories\n(47)\n63\nDecrease in trade and other payables\n(167)\n(286)\nOperating cash flows before interest and tax paid\n(10,618)\n(9,108)\nR&D tax credits received\n684\n896\nTax paid\n(238)\n(82)\nNet cash used in operating activities\n(10,172)\n(8,294)\nInvesting activities\nInterest received\n110\n71\nPurchases of property, plant and equipment\n(80)\n(250)\nPurchases of intangible assets\n(515)\n(466)\n(Increase) / decrease in term deposits\n(1,000)\n25\nNet cash used in investing activities\n(1,485)\n(620)\nFinancing activities\nInterest paid\n(225)\n(213)\nRepayment of lease liabilities\n(622)\n(723)\nAcquisition of minority interest shares in subsidiary entity\n-\n-\nIssue of equity shares and warrants\n9,860\n15,387\nTransaction costs relating to issue of equity shares\n(759)\n(1,244)\nNet cash generated by financing activities\n8,254\n13,207\nNet (decrease) / increase in cash and cash equivalents\n(3,403)\n4,293\nForeign exchange movement on cash and cash equivalents\n(20)\n(17)\nCash and cash equivalents at beginning of year\n23\n5,250\n974\nCash and cash equivalents at end of year\n1,827\n5,250\n1. Corporate information\nOxford Biodynamics plc is a public limited company incorporated in the United Kingdom, whose shares were admitted to trading on the AIM market of the London Stock Exchange on 6 December 2016.\u00a0The Company is domiciled in the United Kingdom and its registered office is 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB. The registered company number is 06227084 (England & Wales).\nThe Group is primarily\u00a0engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development.\n2. Basis of the announcement\nBasis of preparation\nThe final results for the year ended 30 September 2024 were approved by the Board of Directors on 27 February 2025. The final results do not constitute full accounts within the meaning of section 434 of the Companies Act 2006 but are derived from audited accounts for the year ended 30 September 2024 and the year ended 30 September 2023.\nThis announcement is prepared on the same basis as set out in the audited statutory accounts for the year ended 30 September 2024. The accounts for the years ended 30 September 2024 and 30 September 2023, upon which the auditors issued unqualified opinions, also had no statement under section 498(2) or (3) of the Companies Act 2006. The auditors' report includes reference to the material uncertainties relating to going concern. See below for more details of the going concern assessment performed by the Board of Directors.\nWhile the financial information included in this results announcement has been prepared in accordance with the recognition and measurement criteria of International Financial Reporting Standards in conformity with the Companies Act 2006 (IFRS), this announcement does not in itself contain sufficient information to comply with IFRS.\nReporting currency\nThe consolidated financial statements are presented in pounds sterling (GBP), which is also the Company's functional currency.\nDisclosure of tax receivable\nThe Directors have reviewed the previous disclosure of tax receivable and, in order to comply with the requirements of IAS 1 'Presentation of Financial Statements', have represented the relevant balances separately in the Group and Company statements of financial position. There is no impact on any asset subtotals in either the current or prior year as a result of this additional disclosure.\nGoing concern\nIn assessing the appropriateness of adopting the going concern assumption, the Group and Parent Company has prepared a detailed financial forecast (\"the Baseline Forecast\") covering the period ending 31 March 2026. The Baseline Forecast includes:\n\u00b7\nestimates of likely revenue arising from EpiSwitch PSE and EpiSwitch CiRT;\n\u00b7\nanticipated revenues from contracts with pharmaceutical partners;\n\u00b7\noperating costs reflecting the current cost base including recently initiated cost-saving actions;\n\u00b7\ncapital expenditure, primarily to maintain and extend the Group's patent estate.\nRevenue for the year ended 30 September 2024 was slightly increased compared to the previous year, but the Group remained lossmaking, with increased costs and operating loss compared to the prior year.\nThe Group was able to maintain its cash reserves during the year, including through a placing, subscription and PrimaryBid offer of new ordinary shares issued in April 2024 that raised \u00a39.9m before expenses. Although sales of the Group's proprietary tests increased over the year to 30 September 2024, this was more than offset by higher operating expenses and the Group required additional cash resources by early in the first quarter of 2025. There was a significant reduction in the Company's share price over the year ended 30 September 2024 and this trend continued after the year end.\nIn October 2024, the Board announced that it had initiated a number of cost-saving actions and a review of the strategic options open to the Company. Following the announcement of the appointment of Iain Ross as Executive Chairman, the Company successfully raised a total of \u00a37.35m before expenses in January 2025.\nUnder this new leadership, the Company has indicated that it will operate with a renewed focus on partnerships, collaboration and licensing in order to monetise the Group's assets. To that end, the Group is currently involved in discussions, at various stages of development with multiple interested parties.\nIn addition to the Baseline Forecast, the Group and Parent Company has prepared an \"Upside Forecast\" that reflects the Directors' intention to agree partnerships, collaborations and/or licensing over the remainder of 2025. In addition, the Upside Forecast also reflects higher sales of the EpiSwitch PSE test than the Baseline Forecast, which are expected to arise from agreements with new distributors and/or expansion of coverage of the test by UK private health insurers.\nAs noted in the Executive Chairman's report, Iain Ross is currently leading a review of all of the Group's operations and expects to share the outcome of that review along with further progress around the time of the Company's annual general meeting in March 2025. Any additional potential cost reduction actions that may be taken as a result of this review have not been reflected in the Upside Forecast.\nIn the scenario reflected in the Baseline Forecast, the Company would need to generate additional funding during the final quarter of 2025. Should this forecast not be met (in a downside scenario) the quantum of any additional funding may need to be increased and/or the timing accelerated. With the income reflected in the Upside Forecast, cash resources would be expected to last beyond 31 March 2026.\nWhilst the Board considers that the Upside Forecast represents a reasonable estimate of the Group's potential performance over the period to 31 March 2026, for the purposes of their assessment as to whether the Group and Parent Company would be able to continue as a going concern, the Directors referred to the Baseline Forecast.\nIn the Baseline Forecast, in the absence of income from partnership, collaboration or out-licensing, the availability of additional funding to enable the Group and Parent Company to continue as a going concern would be expected to depend on the Group having demonstrated either significant progress towards such a partnership, collaboration or out-licensing agreement or materially increased sales of its proprietary tests. The Directors expect that it will be possible to demonstrate such progress, but draw attention to significant uncertainties inherent in the preparation of the Baseline Forecast. As in the prior year, these primarily relate to balances associated with the revenue / income cycle, since most of the Group's costs are reasonably predictable. These uncertainties include volumes of orders of the Group's tests; the proportion of PSE test sales that are covered by US health insurance; reimbursement rates and timing of the reimbursement cycle (and consequent impact on the Group's working capital); and the number and value of new agreements with pharma/biotech customers.\nAs noted above, the Company raised a total of \u00a37.35m (before expenses) from new and existing shareholders after the year end in January 2025. Whilst the fundraise was successful, it was carried out at a historically low issue price per share and involved significant dilution for non-participating shareholders. There is no guarantee that the Company will be able to access further cash resources from investors in future.\nThese conditions (that is, the uncertainties relating to revenue generation and the ability to raise further funds) represent material uncertainties which may cast significant doubt on the Group and Parent Company's ability to continue as a going concern and, therefore, it may be unable to realise its assets and discharge its liabilities in the normal course of business.\nNotwithstanding these material uncertainties, based on all the above considerations, the Directors confirm that they have a reasonable expectation that the Group and Company has adequate resources to continue in operational existence for the foreseeable future, being the period to 31 March 2026. Accordingly, the Directors continue to adopt the going concern basis of preparation of the Group and Company financial statements.\nCritical judgements in applying the Group's accounting policies\nThe following are the critical judgements that the Directors have made in the process of applying the Group's accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements.\nTreatment of revenue arising from test sales reimbursed by US insurance payors\nThe Group recognises revenue when or as the relevant performance obligations in its contracts with customers are completed. Sales of the Group's proprietary tests can be paid for by patients, payors with whom the Group has direct agreements in place, or by US insurers through the reimbursement process. In this final case, the Group may obtain an acknowledgement of financial responsibility from a patient before processing a test.\nEpiSwitch\u00ae CiRT and PSE tests were regularly reimbursed by several US insurers throughout the year, for a range of amounts, and this has continued post-year end. The amount received is influenced by several factors, including the terms of individual patients' policies such as requirements for co-payment, the price listed for the test, if any, in the Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Fee Schedule (CLFS), insurers' own coverage policies in respect of the tests, and claim denials. Where reimbursement for a test is initially denied, or reimbursed at a lower-than-expected amount, the Group avails itself of the appeals process that exists in the reimbursement system. At the year end, a number of appeals were in process but not yet complete. Reimbursement claims for a further group of processed tests were held by the Group pending confirmation of coverage decisions by insurers or the relevant Medicare Administrative Contractor (MAC), in order to ensure the most positive likely outcome in terms of eventual reimbursement.\nThe above factors are relevant to Management's decision on whether a contract with a customer exists and therefore whether the five-step process of revenue recognition included in IFRS 15\nRevenue from Contracts with Customers\nshould be followed or whether instead revenue should be recognised on final receipt of funds from a payor.\nManagement exercised judgement in determining that for the Group's test orders in the period, the patient should be considered the customer, even if there is no explicit reimbursement agreement in place between the Group and the patient, the contract with the patient being judged to be established in accordance with customary business practices.\nFor the Group's clinical tests, since reimbursement ultimately received from insurers is variable, Management must exercise judgement in determining the amount and timing of revenue to be recognised.\nFollowing the guidance in IFRS 15, Management limits the amount of variable consideration recognised to the \"unconstrained\" portion of such consideration. This means that the Group recognises revenue up to the amount of variable consideration that is not subject to a potential significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds is subsequently resolved. Up to 30 September 2024, the Group still had limited detailed historical data from which to reliably predict receipts from insurers and therefore the amount of variable consideration to recognise on delivery of a test report to a patient's doctor. In practice, this means that variable consideration arising from insurance-reimbursed clinical tests has been constrained to zero, until receipt of reimbursements from insurers.\nThe effect of this judgement is to delay revenue recognition, in the case of tests processed by the Group's partner laboratory to later than the recognition of cost of sales. To the extent that this judgment were to be inappropriate, the Group's revenue for the period would be increased, but Management do not expect that this would result in any material change to the amounts recognised in these financial statements.\nManagement anticipate that in future periods, as the Group's historical collections experience increases in volume and specificity in relation to particular payors and policies it is likely that judgement will continue to be required in determining the extent to which variable consideration relating to these tests is unconstrained and should therefore be recognised.\nIdentification of the Group's cash-generating unit\nIn carrying out the impairment review of patent assets set out in more detail below, Management exercised judgement in determining that the Group currently has one cash-generating unit (CGU). Guidance states that CGUs are \"the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows for other assets or groups of assets\".\nThe Group's strategy was expanded in December 2020, to include the development and commercialisation of proprietary tests. As at 30 September 2024, three lab developed test products had been launched, with two of these (EpiSwitch\u00ae CiRT and EpiSwitch\u00ae PSE) being actively marketed as well as the Group's EpiSwitch\u00ae Explorer Array Kit, which is marketed to the life science research community. Revenue from products and customer contracts is reported separately to Directors in the Group's internal management accounts. However, it is not currently possible to assign separate groups of OBD assets to particular cashflows. With very limited exceptions, people, premises, equipment and patents are generally applied to both product and customer contract revenue streams. This position may change as i) dedicated product sales and marketing teams are more fully developed, ii) the Group's LDTs are consistently processed through the Group's US and UK clinical laboratories and iii) test-specific revenue streams become more predictable.\nAt present, Management continues to conclude that the Group has one CGU, relating to all commercial exploitation of its EpiSwitch\u00ae technology. If a different judgement were taken and the Group determined to contain more than one separately identifiable CGU, as part of the impairment review of the Group's patent assets conducted at the year end, it would have been necessary to estimate the recoverable value of each CGU separately and to allocate patents to those CGUs.\nImpairment review\nIntangible assets are reviewed for indicators of impairment at the end of each reporting period. An impairment review of patent and other assets was conducted as at the year end, because there were a number of indicators of potential impairment, including the significant reduction during the year of the Company's share price and market capitalisation and the Group's financial performance for the year resulting in a larger than expected loss. In addition, an impairment review is required for any assets not yet being amortised and certain patent assets fall into this category.\nAs noted above, Management identified that at the current stage in the Group's development, it includes a single CGU, to which all patent assets are allocated. Management consider that the recoverable amount of the Group's single CGU is based on its fair value less cost of disposal (FVLCOD), and that this value is attributable to its intellectual property, including patents and know-how, and its other assets, including property plant and equipment. The most reliable available estimate for the fair value of the Group's CGU as a whole is the enterprise value of the Group, which is in turn given by the market value of the Company on a cash- and debt-free basis.\nAs at 30 September 2024, the Group had a market capitalisation of \u00a310m (3.22p x 311,855,650 shares then in issue). Cash/cash equivalents and term deposits at 30 September 2024 of \u00a32.8m are deducted from market value in arriving at the enterprise value. Following review of available guidance, Management determined that neither the warrant nor the lease liabilities associated with the Group's rented property should be added back to the market value in determining the enterprise value. This results in an estimate of the year-end enterprise value of the Group as a whole of approximately \u00a37.2m.\nIn estimating the cost of disposal (COD), Management used an estimate of \u00a31.2m, representing a COD of approximately 12% of the year end market value, which is within the range of estimates of disposal costs reviewed by Management. The FVLCOD of the Company as at 30 September 2024 was therefore estimated to be \u00a36m. Management then compared the FVLCOD of the Company to the carrying value of the Group's assets excluding patents (\u00a31.86m in respect of property plant and equipment and capitalised software). The excess of the Company's FVLCOD over its gross assets excluding patents was therefore approximately \u00a34.1m, compared to a carrying value of patent assets (after patent-specific impairment charges noted above) of \u00a31.24m. Management therefore concluded that no further impairment of the Company's capitalised patents existed at the year end.\nManagement considers that a reduction in the Company's estimated FVLCOD to an amount comparable to the carrying value of its non-patent assets would lead to a reduction in the recoverable amount of its patent assets, potentially to nil. Management will continue to assess, at the end of each reporting period and more frequently if necessary, whether there are indicators that any of the Group's assets may be impaired or that impairment charges recognised in the period require reversal.\nIntangible assets\nAs at the year end, the Group had limited cash resources and Management's plans for near-term commercialisation were focused on a limited number of pipeline assets, alongside tests already launched and the EpiSwitch platform itself. In the light of this, Management further reviewed each of the Company's patent families for other indicators of impairment, principally considering whether amounts previously capitalised remain supportable by an assessment of likely future economic benefits, bearing in mind these more focused short-to-medium-term plans.\nThe Company is continuing to pursue, and where relevant renew, each of the individual patents in its 22 patent families, but in line with the guidance in the relevant accounting standards, Management determined that an impairment charge of \u00a30.9m should be recognised in the period.\n3.\nRevenue\nAll revenue is derived from the Group's principal activities, namely sales of proprietary products and biomarker research and development. Analysis of the Group's revenue by principal activities, geography and pattern of revenue recognition is as follows:\n2024\n2023\n\u00a3000\n\u00a3000\nContinuing operations:\nSales of proprietary products\nUSA\n345\n160\nRest of World\n63\n34\n408\n194\nBiomarker research and development\nUSA\n114\n228\nRest of World\n114\n88\n228\n316\nConsolidated revenue\n636\n510\n2024\n2023\n\u00a3000\n\u00a3000\nContinuing operations:\nRevenue recognised at a point in time\n408\n194\nRevenue recognised over time\n228\n316\n636\n510\nInformation about major customers\nThe Group's revenues for the periods covered by this report are derived from a small number of customers, several of which represent more than 10% of the revenue for the period. These are summarised below:\n2024\n2023\n\u00a3000\n\u00a3000\nRevenue from individual customers each representing more than 10%\nof revenue for the period:\n170\n280\nNumber\nNumber\nNumber of individual customers each representing more than 10%\nof revenue for the period.\n2\n2\n4. Other operating income\n2024\n2023\n\u00a3000\n\u00a3000\nContinuing operations:\nAward and grant income\n476\n827\nIncome was recognised in both years in respect of each of the Company's PACT awards and OBD's involvement in the EU-funded HIPPOCRATES consortium.\n5. Business segments\nProducts and services from which reportable segments derive their revenues\nInformation reported to the Group's Chief Executive Officer (who was determined to be the Group's Chief Operating Decision Maker during the year) for the purposes of resource allocation and assessment of segment performance is focused on costs incurred to support the Group's main activities. The Group is currently determined to have one reportable segment under IFRS 8, that of sales of proprietary products and biomarker research and development. This assessment will be kept under review as the Group's activity expands.\nThe Group's operating expenses and non-current assets, analysed by geographical location were as follows\n:\n2024\n2023\n\u00a3000\n\u00a3000\nStaff costs\nUK\n2,531\n2,614\nUSA\n2,869\n2,692\nRest of World\n95\n97\nTotal staff costs\n5,495\n5,403\nResearch & development costs\nUK\n540\n680\nUSA\n269\n77\nRest of World\n-\n1\nTotal research & development costs\n809\n758\nGeneral & other admin costs\nUK\n2,598\n2,399\nUSA\n1,837\n969\nRest of World\n44\n43\nTotal general & other admin costs\n4,479\n3,411\nNon-current assets\nUK\n6,025\n7,446\nUSA\n1,015\n1,478\nRest of World\n22\n36\nTotal non-current assets\n7,062\n8,960\n6. Loss for the year\nLoss for the year has been arrived at after charging/(crediting):\n2024\n2023\n\u00a3000\n\u00a3000\nNet foreign exchange losses\n298\n(31)\nResearch and development costs (excluding staff costs)\n809\n758\nAmortisation of intangible assets\n171\n146\nDepreciation of property, plant and equipment\n550\n548\nDepreciation of right-of-use assets\n745\n663\nImpairment loss on intangible assets\n896\n-\nStaff costs\n5,495\n5,403\nShare-based payments charged to profit and loss\n514\n332\nFair value loss / (gain) on financial liabilities designated as FVTPL\n(1,349)\n1,246\nGain reclassified to profit or loss on disposal of foreign operation\n-\n(113)\n7. Earnings per share\nFrom continuing operations\nThe calculation of the basic and diluted earnings per share is based on the following data:\n2024\n2023\n\u00a3000\n\u00a3000\nEarnings for the purposes of basic earnings per share being net loss attributable to owners of the Company\n(11,567)\n(10,826)\nEarnings for the purposes of diluted earnings per share\n(11,567)\n(10,826)\n2024\n2023\nNo\nNo\nNumber of shares\nWeighted average number of ordinary shares for the purposes of\nbasic and diluted earnings per share*\n255,728,889\n147,481,566\nPence\nPence\nEarnings per share\nBasic and diluted earnings per share\n(4.5)\n(7.3)\n*Ordinary shares that may be issued on the exercise of options or warrants are not treated as dilutive as the entity is loss-making.\nThe issue of shares post year end, as set out in note 15, would have significantly changed the number of ordinary shares outstanding at the end of the year had that transaction occurred prior to the year end\n8. Intangible fixed assets\nGroup\nWebsite development costs\nSoftware development costs\nPatents\nTotal\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\nCost\nAt 1 October 2023\n62\n173\n2,101\n2,336\nAdditions\n-\n90\n425\n515\nDerecognition of assets\n-\n-\n(997)\n(997)\nExchange differences\n-\n(17)\n-\n(17)\nAt 30 September 2024\n62\n246\n1,529\n1,837\nAccumulated amortisation\nAt 1 October 2023\n62\n99\n262\n423\nCharge for the year\n-\n53\n118\n171\nDerecognition of assets\n-\n-\n(101)\n(101)\nExchange differences\n-\n(7)\n-\n(7)\nAt 30 September 2024\n62\n145\n279\n486\nCarrying amount\nAt 30 September 2024\n-\n101\n1,250\n1,351\nGroup\nWebsite development costs\nSoftware development costs\nPatents\nTotal\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\nCost\nAt 1 October 2022\n62\n144\n1,674\n1,880\nAdditions\n-\n39\n427\n466\nExchange differences\n-\n(10)\n-\n(10)\nAt 30 September 2023\n62\n173\n2,101\n2,336\nAccumulated amortisation\nAt 1 October 2022\n62\n65\n152\n279\nCharge for the year\n-\n36\n110\n146\nExchange differences\n-\n(2)\n-\n(2)\nAt 30 September 2023\n62\n99\n262\n423\nCarrying amount\nAt 30 September 2023\n-\n74\n1,839\n1,913\nAs at 30 September 2024, in the Group, a total of \u00a3nil (2023: \u00a3304,000) of patent assets were not yet being amortised because their useful life was determined not to have begun.\nThe derecognition of assets with a carrying value of \u00a3896,000 has been presented as an impairment in the consolidated income statement. These assets continue to be held and maintained by the Group.\nThe Group hold no intangible assets that are determined to have indefinite useful life.\n9. Property, plant and equipment\nGroup\nLeasehold\nimprovements\nOffice\nequipment\nFixtures\nand fittings\nLaboratory\nequipment\nTotal\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\nCost\nAt 1 October 2023\n2,084\n191\n185\n2,300\n4,760\nAdditions\n15\n16\n2\n61\n94\nDisposals\n-\n(3)\n-\n(327)\n(330)\nExchange differences\n-\n(5)\n(1)\n(34)\n(40)\nAt 30 September 2024\n2,099\n199\n186\n2,000\n4,484\nAccumulated depreciation\nAt 1 October 2023\n437\n127\n77\n1,881\n2,522\nCharge for the year\n211\n36\n35\n268\n550\nEliminated on disposals\n-\n(3)\n-\n(327)\n(330)\nExchange differences\n-\n(2)\n-\n(18)\n(20)\nAt 30 September 2024\n648\n158\n112\n1,804\n2,722\nCarrying amount\nAt 30 September 2024\n1,451\n41\n74\n196\n1,762\nGroup\nLeasehold\nimprovements\nOffice\nequipment\nFixtures\nand fittings\nLaboratory\nequipment\nTotal\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\n\u00a3000\nCost\nAt 1 October 2022\n2,041\n182\n172\n2,318\n4,713\nAdditions\n45\n58\n15\n125\n243\nDisposals\n-\n(47)\n-\n(88)\n(135)\nExchange differences\n(2)\n(2)\n(2)\n(55)\n(61)\nAt 30 September 2023\n2,084\n191\n185\n2,300\n4,760\nAccumulated depreciation\nAt 1 October 2022\n231\n139\n44\n1,717\n2,131\nCharge for the year\n208\n37\n34\n269\n548\nEliminated on disposals\n-\n(47)\n-\n(84)\n(131)\nExchange differences\n(2)\n(2)\n(1)\n(21)\n(26)\nAt 30 September 2023\n437\n127\n77\n1,881\n2,522\nCarrying amount\nAt 30 September 2023\n1,647\n64\n108\n419\n2,238\n10. Right-of-use assets\nGroup\nBuildings\nOther\nTotal\n\u00a3000\n\u00a3000\n\u00a3000\nCost\nAt 1 October 2023\n6,241\n18\n6,259\nAdditions\n18\n-\n18\nDerecognition\n(12)\n-\n(12)\nExchange differences\n(112)\n-\n(112)\nAt 30 September 2024\n6,135\n18\n6,153\nAccumulated depreciation\nAt 1 October 2023\n1,483\n17\n1,500\nCharge for the year\n744\n1\n745\nEliminated on derecognition\n(12)\n-\n(12)\nExchange Differences\n(29)\n-\n(29)\nAt 30 September 2024\n2,186\n18\n2,204\nCarrying amount\nAt 30 September 2024\n3,949\n-\n3,949\nGroup\nBuildings\nOther\nTotal\n\u00a3000\n\u00a3000\n\u00a3000\nCost\nAt 1 October 2022\n5,224\n18\n5,242\nAdditions\n1,029\n-\n1,029\nDerecognition\n-\n-\n-\nExchange differences\n(12)\n-\n(12)\nAt 30 September 2023\n6,241\n18\n6,259\nAccumulated depreciation\nAt 1 October 2022\n835\n11\n846\nCharge for the year\n657\n6\n663\nEliminated on derecognition\n-\n-\n-\nExchange Differences\n(9)\n-\n(9)\nAt 30 September 2023\n1,483\n17\n1,500\nCarrying amount\nAt 30 September 2023\n4,758\n1\n4,759\n11. Share capital of the company\n2024\n2024\n2023\n2023\nNumber\n\u00a3\nNumber\n\u00a3\nAuthorised shares\nOrdinary shares of \u00a30.01 each - allotted and fully paid\n311,855,650\n3,118,557\n202,303,415\n2,023,034\nTotal\n311,855,650\n3,118,557\n202,303,415\n2,023,034\nAt 30 September 2024, the Company had one class of ordinary shares which carry no right to fixed income.\nOn 5 April 2024 and 8 April 2024, the Company issued a total of 109,552,235 new ordinary shares at an issue price of \u00a30.09 per share raising gross proceeds of \u00a39.9m with issuance costs of \u00a30.8m.\nNo shares were issued on the exercise of share options or warrants during the year (2023: nil).\nThe Company has a number of shares reserved for issue pursuant to warrants and under an equity-settled share option scheme; further details are disclosed in Notes 12 and 14.\nAfter the year end:\nOn 28 October 2024, the Company issued 2,285,741 new ordinary shares.\nOn 29 November 2024, the Company issued 2,435,178 new ordinary shares.\nOn 24 December 2024, the Company issued 2,742,657 new ordinary shares.\nOn 31 January 2025, the shareholders of the Company approved a share capital reorganisation, whereby each of the 319,319,226 ordinary shares of \u00a30.01 each in the capital of the Company then in issue was sub-divided and re-designated as one new ordinary share of\u00a0\u00a30.001\u00a0each in the capital of the Company and one deferred share of\u00a0\u00a30.009\u00a0each in the capital of the Company. Following the Share Capital Reorganisation, there were 319,319,226 ordinary shares of\u00a0\u00a30.001\u00a0each and 319,319,226 deferred shares of\u00a0\u00a30.009 each.\nAs all of the existing ordinary shares were sub-divided and re-designated, the proportion of the issued share capital of the Company held by each shareholder immediately following the share capital reorganisation remained unchanged. In addition, apart from having a different nominal value, each ordinary share with a nominal value of\u00a0\u00a30.001\u00a0carries the same rights and represents the same proportionate interest in the Company as an original ordinary share with a nominal value of \u00a30.01.\nThe deferred shares created are effectively valueless as they do not carry any rights to vote or dividend rights. In addition, holders of deferred shares will only be entitled to a payment on a return of capital or on a winding up of the Company after each of the holders of ordinary shares have received a payment of\u00a0\u00a31,000,000\u00a0on each such share. The deferred shares will not be listed on AIM and will not be transferable without the prior written consent of the Board. No share certificates have been issued in respect of the deferred shares, nor will CREST accounts of Shareholders be credited in respect of any entitlement to deferred shares. The Board's intention is that deferred shares will be bought back and cancelled in due course.\nOn 3 February 2025 and 4 February 2025, the Company issued a total of 1,638,258,415 new ordinary shares of \u00a30.001 each.\n12. Warrants\nAs at 30 September 2024 there were 7,791,803 shares reserved for issue under warrants (30 September 2023: 7,791,803).\nThe Warrants were issued on 11 November 2021. The Warrants have an exercise price of 58.125p and may be exercised for a period beginning one year and ending five years after the issue date.\nIn certain circumstances, the Warrants may be exercised by way of a 'cashless exercise' whereby holders are entitled to receive a number of warrant shares equal to [(A-B) x 7,791,803]/(A), where A is the value of the Company's ordinary shares at the time, and B is the warrant exercise price of 58.125p. Anti-dilution provisions are also in place such that if there is an adjustment for any dividends paid or changes to ordinary share capital at any time whilst the warrant is outstanding, the number of shares issued on exercise of the warrant is adjusted to take into account the proportionate change (with a limitation on fractional shares).\nOn award and at each subsequent reporting date, the fair value of the Warrants has been estimated using the Black-Scholes option pricing model. Volatility has been estimated by reference to historical share price data over a period commensurate with the expected term of the options awarded (effectively the remaining term at each reporting date).\nThe fair value of the Warrants and the assumptions used in estimating it are shown below:\n30 September 2024\n30 September 2023\nShare price at reporting date (p)\n3.2\n37\nExercise price (p)\n58.125\n58.125\nExpected volatility\n98.85%\n84.39%\nDividend yield\n0%\n0%\nExpected life of option\n2.11 years\n3.11 years\nRisk free interest rate\n3.82%\n4.55%\nFair value per Warrant\n0.2p\n17p\nWarrant liability\n\u00a311,000\n\u00a31,360,000\nWarrant liability\n- Group and Company\nTotal\n\u00a3000\nAt 1 October 2023\n1,360\nIssue of warrants\n-\nFair value gain on financial liability designated as FVTPL\n(1,349)\nAt 30 September 2024\n11\nAt 1 October 2022\n114\nIssue of warrants\n-\nFair value loss on financial liability designated as FVTPL\n1,246\nAt 30 September 2023\n1,360\n13. Lease liabilities\nGroup\n2024\n2023\nMaturity analysis:\n\u00a3000\n\u00a3000\nYear 1\n1,236\n1,045\nYear 2\n1,030\n1,052\nYear 3\n1,036\n1,051\nYear 4\n1,042\n1,058\nYear 5+\n2,020\n3,101\n6,364\n7,307\nLess: future interest charges\n(624)\n(868)\n5,740\n6,439\nAnalysed as:\nCurrent\n1,046\n818\nNon-current\n4,694\n5,621\n5,740\n6,439\n14. Share-based payments\nEquity-settled share option scheme\nIn November 2016, the Company established an Enterprise Management Incentive (\"EMI\") share option scheme, under which options have been granted to certain employees, and a non-employee option scheme with similar terms, except that options granted under it do not have EMI status. EMI and non-EMI share options were also previously granted under a share option scheme established in October 2008 (\"the 2008 Scheme\"). The Company does not intend to grant any further options under the 2008 Scheme. All of the schemes are equity-settled share-based payment arrangements, whereby the individuals are granted share options of the Company's equity instruments, namely ordinary shares of 1 pence (0.1 pence following the share capital reorganisation that took place on 31 January 2025) each.\nThe schemes include non-market-based vesting conditions only, whereby the share options may be exercised from the date of vesting until the 10th anniversary of the date of the grant. In most cases options vest under the following pattern: one-third of options granted vest on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary.\nThe options outstanding as at 30 September 2024 have exercise prices in the range of \u00a30.09 to \u00a32.10.\n2024\n2023\nNumber of\noptions\nWeighted\naverage\nexercise\nprice\nNumber of\nOptions\nWeighted\naverage\nexercise\nprice\n\u00a3\n\u00a3\nOutstanding at start of period\n9,983,143\n0.57\n9,447,658\n0.67\nGranted during the period\n14,048,020\n0.15\n2,721,061\n0.18\nForfeited during the period\n(1,026,668)\n(0.53)\n(2,185,576)\n(0.48)\nExercised during the period\n-\n-\n-\n-\nOutstanding at end of period\n23,004,495\n0.32\n9,983,143\n0.57\nExercisable at end of period\n7,506,823\n0.67\n5,983,853\n0.76\nWeighted average remaining contractual life (in years) of options outstanding at the period end\n7.94\n6.60\n2024\n2023\n\u00a3000\n\u00a3000\nExpense arising from share-based payment transactions\n514\n332\nThe fair value of share options has been estimated using the Black-Scholes option pricing model. Volatility has been estimated by reference to historical share price data over a period commensurate with the expected term of the options awarded. The assumptions for the options granted during the current and prior periods were as follows:\n2024\n2023\n\u00a3000\n\u00a3000\nShare price at date of grant\n\u00a30.06 to \u00a30.34\n\u00a30.156 to \u00a30.189\nExercise price\n\u00a30.09 to \u00a30.34\n\u00a30.156 to \u00a30.189\nExpected volatility\n67% to 69%\n55% to 56%\nDividend yield\n0%\n0%\nExpected life of option\n9.0 to 9.1 years\n8.7 to 9.0 years\nRisk free interest rate\n3.88% to 4.65%\n3.45% to 3.70%\n15. Events after the balance sheet date\nOn 19 December 2024, the Company announced that it had entered an interest free loan agreement with Vulpes Testudo Fund to provide up to \u00a31m in working capital to enable it to continue to pursue funding options.\nOn 17 January 2025, the Company announced that it had successfully raised gross proceeds of approximately \u00a37.35m via the issue of 1,470,002,778 new ordinary shares by way of a placing, subscriptions and retail offer, as disclosed in note 11. The new shares were ultimately issued on 3 and 4 February 2025.\nNotes for Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently\nOBD\nhas two commercially available products: the\nEpiSwitch\u00ae PSE\n(EpiSwitch Prostate Screening test)\nand\nEpiSwitch\u00ae CiRT\n(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.\nCiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch\u00ae\u00a0which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.\nOBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.\nThe Group's headquarters and\u00a0UK\u00a0laboratories are in\u00a0Oxford, UK. Its US operations and clinical laboratory are in\u00a0Maryland, USA, along with a reference laboratory in Penang,\u00a0Malaysia.\nOBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website,\nwww.oxfordbiodynamics.com\n, X (@OxBioDynamics) or\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nFR FDLLLELLLBBL"
        },
        {
          "title": "Notice of Results",
          "announcement_date": "9th Dec 2025",
          "release_time": "12:40 pm",
          "source": "RNS",
          "content": "9 Dec 2025 12:40\nRNS Number : 8696K\nOxford BioDynamics PLC\n09 December 2025\n9 December 2025\nOxford BioDynamics Plc\n(\n\"\nOBD\n\" or the \"\nCompany\n\" and, together with its subsidiaries, the \"\nGroup\n\"\n)\nNotice of Results\nOxford, UK - 9 December 2025\n-\nOxford BioDynamics Plc (AIM: OBD, the Company),\na precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch\u00ae 3D genomics platform,\nexpects to announce its results for the year ended 30 September 2025 on Tuesday 16 December 2025.\n-Ends-\nFor further details please contact:\nOxford BioDynamics Plc\nTel: +44 (0)1865 518910\nIain Ross, Executive Chairman\nPaul Stockdale, CFO\nShore Capital - Nominated Adviser and Broker\nTel: +44 (0)20 7408 4090\nStephane Auton / Lucy Bowden\nOAK Securities - Joint Broker\nTel: +44 (0)20 3973 3678\nMatthew Clarke / Tim Dainton / Calvin Man\nCamarco - Financial PR\nTel: +44 (0)20\u00a03757 4980\nMarc Cohen / Tilly Butcher / Fergus Young\nOBDFinancial@camarco.co.uk\nNotes to Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently\u00a0OBD\u00a0has two commercially available products: the\nEpiSwitch\u00ae PSE\n(EpiSwitch Prostate Screening test)\u00a0and\nEpiSwitch\u00ae CiRT\n(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.\u00a0CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch\u00ae\u00a0which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.\nOBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.\nThe Group's headquarters and\u00a0UK\u00a0laboratories are in\u00a0Oxford, UK. Its US operations and clinical laboratory are in\u00a0Maryland, USA, along with a reference laboratory in Penang,\u00a0Malaysia.\nOBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website,\nwww.oxfordbiodynamics.com\n, X (@OxBioDynamics) or\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORLKLFBELLXFBD"
        },
        {
          "title": "Statement re share price, update on EpiSwitch PSE",
          "announcement_date": "3rd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "3 Dec 2025 07:00\nRNS Number : 9713J\nOxford BioDynamics PLC\n03 December 2025\n3 December 2025\nOxford BioDynamics Plc\n(\n\"\nOBD\n\" or the \"\nCompany\n\" and, together with its subsidiaries, the \"\nGroup\n\"\n)\nStatement re share price movement, update on EpiSwitch PSE\nThe Board of Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch\u00ae 3D genomics platform, notes the recent movement in the Company's share price following the publication on 28 November of the UK National Screening Committee's (NSC) draft recommendation in respect of prostate cancer screening.\nThe NSC's draft recommendation has no direct impact on OBD or the Group's EpiSwitch PSE test. PSE test sales in the US and to private healthcare in the UK have continued to increase, with six successive record months reported from June to November 2025.\n-Ends-\nFor further details please contact:\nOxford BioDynamics Plc\nTel: +44 (0)1865 518910\nIain Ross, Executive Chairman\nPaul Stockdale, CFO\nShore Capital - Nominated Adviser and Broker\nTel: +44 (0)20 7408 4090\nStephane Auton / Lucy Bowden\nOAK Securities - Joint Broker\nTel: +44 (0)20 3973 3678\nMatthew Clarke / Tim Dainton / Calvin Man\nCamarco - Financial PR\nTel: +44 (0)20\u00a03757 4980\nMarc Cohen / Tilly Butcher / Fergus Young\nOBDFinancial@camarco.co.uk\nNotes to Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently\u00a0OBD\u00a0has two commercially available products: the\nEpiSwitch\u00ae PSE\n(EpiSwitch Prostate Screening test)\u00a0and\nEpiSwitch\u00ae CiRT\n(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.\u00a0CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch\u00ae\u00a0which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.\nOBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.\nThe Group's headquarters and\u00a0UK\u00a0laboratories are in\u00a0Oxford, UK. Its US operations and clinical laboratory are in\u00a0Maryland, USA, along with a reference laboratory in Penang,\u00a0Malaysia.\nOBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website,\nwww.oxfordbiodynamics.com\n, X (@OxBioDynamics) or\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nSPMDZMGZMZKGKZZ"
        }
      ],
      "themes": [
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 806,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 53,
      "momentum_score": 79.23,
      "trend_direction": "UP",
      "intelligence_signal": "RETAIL_FOMO_PEAK",
      "activity_level": "HIGH"
    },
    "volatility": {
      "atr_normalized": null,
      "stddev_20d": null
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +10 (AI_Technical_Score=8.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=87.9%)",
      "Volume confirmation: +10 (Relative_Volume=2.4)",
      "Pattern reliability: +0 (Rally_Count=0.0)",
      "Upside history: +2 (best_rally_pct=4%)"
    ],
    "technical_score": {
      "points": 10,
      "ai_score": 8.0,
      "reason": "AI Technical Score 8.0/20 translates to 10/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 87.9,
      "reason": "Drawdown of 87.9% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.43,
      "reason": "Relative volume 2.43x gives 10 points"
    },
    "pattern_score": {
      "points": 0,
      "rally_count": 0.0,
      "reason": "0.0 historical rallies gives 0/15 points"
    },
    "upside_score": {
      "points": 2,
      "best_rally_pct": 4.33,
      "reason": "Best rally of 4% gives 2/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=TOO_EARLY",
          "current_return_pct=-4.3%"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Triangulation not loaded (RNS/social/trends missing)",
        "tag": "HIGH",
        "evidence": [
          "analysis_mode=HISTORICAL_ONLY",
          "confidence_capped_at_65"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "TOO_EARLY",
    "run_multiple": -0.29,
    "current_run_pct": -4.33,
    "avg_historical_run_pct": 4.33
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows TOO_EARLY timing with 40/100 APEX score. Historical data shows 0 rallies averaging 4% upside. Current position: -4.3%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "TOO_EARLY means you can get chopped before real move"
    ],
    "timing_translation": "It might be starting, but not proven yet. Wait for base + volume + catalysts.",
    "confidence_explained": "Confidence 50/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": false,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}